CSL says its CSL112 did not meet the primary efficacy endpoint in the Phase 3 AEGIS-II trial evaluating the highly-anticipated cholesterol efflux enhancer in reducing the risk of major adverse cardiovascular events. …
Disappointment as CSL's leading heart candidate misses in clinical trial
February 13, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
BPDInsights one week out with patient voices leading the agenda
May 11, 2026 - - Latest News -
It's mostly a mistake to read too much into a Budget forecast because of what it doesn't include
May 11, 2026 - - Latest News -
Budget silence on HTA Review would confirm what we already know - delayed rollout
May 9, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 8 May 2026
May 8, 2026 - - Podcast -
Lilly marks 150 years by lighting a new horizon for health at Vivid Sydney
May 8, 2026 - - Latest News -
The approaching major change in Australia’s PBS wholesaling arrangements
May 8, 2026 - - Latest News -
Victoria joins state-funded MenB programs as PBAC rejection creates another 'postcode lottery'
May 8, 2026 - - Latest News